# Washington University/Siteman Cancer Center Lead Academic Site

> **NIH NIH UG1** · WASHINGTON UNIVERSITY · 2021 · $1,407,055

## Abstract

Project Summary
The fundamental goal of the proposed Washington University/Siteman Cancer Center
(WU/SCC) NCTN Lead Academic Participating Site UG1 is to 1) foster scientific leadership and
mentorship in the NCTN, 2) participate in the development of NCTN therapeutic, correlative,
and cancer control trials, and 3) maintain strong accrual to clinical trials across multiple disease
sites, including those that are molecularly driven and those for rare cancers. WU/SCC
investigators have a long history of enthusiastic participation in the former cooperative group
program and continue to play key roles in the current NCTN program, specifically the Alliance
for Clinical Trials in Oncology, ECOG-ACRIN Cancer Research Group, and NRG Oncology.
WU/SCC will have 5 UG1 co-Principal Investigators comprising the senior leadership team
including Nancy L. Bartlett, MD (Professor, Medical Oncology), Benjamin Kozower, MD, MPH
(Professor, Thoracic Oncology), David G. Mutch, MD (Professor, Gynecologic Oncology),
Clifford Robinson, MD (Associate Professor, Radiation Oncology) and Barry A. Siegel, MD
(Professor, Radiology). The WU/SCC senior leadership team is composed of three legacy
members with extensive cooperative group and NCTN experience (Bartlett, Mutch and Siegel)
and two new members (Robinson and Kozower) with experience in NCTN trial development.
The entire leadership team is committed to providing guidance for an institution-wide NCTN
UG1. WU/SCC has consistently demonstrated robust accrual to NCTN trials, accruing 848
patients between March 2014 and August 2017. During this same interval, 535 patients had
biospecimens collected and 58 patients were accrued to advanced imaging studies. The
strength of the WU/SCC genomics, proteogenomics, and molecular imaging programs in
combination with the large institutional biorepositories position us to make significant and novel
contributions to the scientific mission of the NCTN. WU/SCC investigators remain highly
invested in NCTN translational and clinical research in AML, lymphoma, lung cancer, breast
cancer, sarcoma, uterine cancer, molecular imaging, and radiation oncology. In addition, our
large referral base and the substantial increase in new cancer cases seen at our center in the
last 5 years will enhance our ability to accrue patients to nearly all disease site protocols,
including rare tumors. This institution-wide UG1 will facilitate enhanced communication and
collaboration among disease-site, translational, and modality specialists and improve our
potential for contributions to the NCTN operation.

## Key facts

- **NIH application ID:** 10114991
- **Project number:** 5UG1CA233339-03
- **Recipient organization:** WASHINGTON UNIVERSITY
- **Principal Investigator:** NANCY L BARTLETT
- **Activity code:** UG1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $1,407,055
- **Award type:** 5
- **Project period:** 2019-03-05 → 2025-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10114991

## Citation

> US National Institutes of Health, RePORTER application 10114991, Washington University/Siteman Cancer Center Lead Academic Site (5UG1CA233339-03). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10114991. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*